Basel, Switzerland, December 10, 2012 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that it has promoted Ronald Scott, previously Chief Operating Officer, to Chief Executive Officer effective January 1, 2013 to succeed Anthony Man, MD, who has decided for personal reasons to leave the company as of December 31, 2012.
"We are very pleased that Ron Scott will assume the role of CEO of Basilea following the decision of Anthony Man to resign. Ron Scott is an esteemed business leader in the pharmaceutical industry with a track record of delivering results and maintaining organization focus on business priorities. With several product candidates including highly competitive late-stage drugs in our pipeline and a strong cash position, Basilea has unique prospects to further create substantial shareholder value," commented Werner Henrich, chairman of Basilea. "Anthony Man is one of the most experienced and respected drug development executives in industry with an exceptional track record in bringing drugs through to the market. We sincerely thank him for his leadership, integrity and resilience in guiding Basilea through very rewarding and challenging times and wish him all the best for his future endeavors."
For the last year Ron Scott served as COO responsible for all of Basilea`s operations including technical operations, commercial activities and finance. Prior to his position as COO he served as Basilea`s CFO. Ron Scott led the company`s equity financings and significant business transactions. Previously he held senior management positions in the pharmaceutical industry with over twenty years of experience and in the financial sector.
Basilea`s Management Committee has been enlarged to include Ms. Heidi McDaid, Head of Global Human Resources effective January 1, 2013. The Management Team`s other members remain Prof. Dr. Achim Kaufhold, Chief Medical Officer since 2010; Dr. Ingrid Heinze-Krauss, Chief Technical Officer since 2006; Dr. Laurenz Kellenberger, Chief Scientific Officer since 2009; and Joachim Blatter, Chief Financial Officer since 2012.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd. ("Basilea") the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Media Relations||Investor Relations|
|Peer Nils Schröder, Ph.D.|
Head Public Relations &
+41 61 606 1102
|Barbara Zink, Ph.D., MBA|
Head Corporate Development
+41 61 606 1233
This press release can be downloaded from www.basilea.com.